Erdafitinib 1346242-81-6 CAS high purity powder directly supply safe delivery
284 Inquiries
1346242-81-6
Pharmaceutical Grade
99%
HK
Shengyufan International Trade Co., Ltd.
sealed foil bag
2027-08-26
Cosmetic raw material,API,Retatrutide,Tirzepatide,Semaglutide,intermediates
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceErdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy. Erdafitinib's innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient's specific genetic mutation. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions. Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward.|Erdafitinib is an oral small molecule inhibitor of fibroblast growth factor receptors (FGFR) 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.|Erdafitinib is an orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.Basic Info-
Product Name:
N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine
Other Name:1,2-Ethanediamine,N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-;N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;Erdafitinib;JNJ 42756493;Balversa;1620332-47-9
CAS No.:1346242-81-6
Molecular Formula:C25H30N6O2
InChIKeys:InChIKey=OLAHOMJCDNXHFI-UHFFFAOYSA-N
Molecular Weight:446.54
Exact Mass:446.54
UNII:890E37NHMV
NCI Thesaurus Code:C103273
ATC Code:L - Antineoplastic and immunomodulating agents
Categories:
Characteristics-
PSA:
77.3
XLogP3:3.2
Density:1.2±0.1 g/cm3
Flash Point:354.4±31.5 °C
Refractive Index:1.618
Water Solubility:<1 mg/mL
Research-
Class:
Pan-FGFR tyrosine kinase inhibitor (FGFR1-4); antineoplastic (ATC L01EN01)
Status:Approved (FDA accelerated approval 2019-04-12; converted to regular approval 2024-01-19; EMA approval 2024-08)
Mechanism:Erdafitinib is an orally bioavailable, functionally selective small-molecule inhibitor of fibroblast growth factor receptors 1-4 (FGFR1-4). It inhibits FGFR tyrosine kinase activity (IC50 1.2-5.7 nM), blocking downstream RAS-MAPK/ERK and PI3K-AKT signaling that drives proliferation and survival of tumor cells harboring activating FGFR alterations (mutations, amplifications, or fusions). Rapid lysosomal uptake contributes to prolonged inhibition of FGFR signaling.
EC50 (Fgfr1 Ic50):1.2 nM
EC50 (Fgfr3 Ic50):3.0 nM
EC50 (Fgfr2 Ic50):2.5 nM
EC50 (Fgfr4 Ic50):5.7 nM
EC50 (Vegfr2 Ic50):36.8 nM (approximately 30-fold selectivity vs FGFR1)
Source:Perera TPS, et al. Mol Cancer Ther. 2017;16(6):1010-1020.DOI
Clinical Development:FDA:Balversa (approved 2019-04-12)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Approval announcement 2024-01-19; FDA: BALVERSA label (NDA 212018, BLC2001); NEJM: Loriot et al. (2023) — THOR Cohort 1; NEJM: Loriot et al. (2019) — BLC2001; Mol Cancer Ther: Perera et al. (2017) — discovery pharmacology
Disclaimer:Erdafitinib (Balversa) is a prescription medicine approved by the US FDA and the EMA for specific oncology indications. ECHEMI lists this product for industrial sourcing and supply-chain reference only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or a substitute for approved therapy. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
Skin sensitization, Sub-category 1B
Serious eye damage, Category 1
Reproductive toxicity, Category 2
Specific target organ toxicity â repeated exposure, Category 1
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H302 Harmful if swallowed
H317 May cause an allergic skin reaction
H318 Causes serious eye damage
H361 Suspected of damaging fertility or the unborn child
H372 Causes damage to organs through prolonged or repeated exposure
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P272 Contaminated work clothing should not be allowed out of the workplace.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P203 Obtain, read and follow all safety instructions before use.
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
P302+P352 IF ON SKIN: Wash with plenty of water/...
P333+P317 If skin irritation or rash occurs: Get medical help.
P321 Specific treatment (see ... on this label).
P362+P364 Take off contaminated clothing and wash it before reuse.
P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P317 Get medical help.
P318 IF exposed or concerned, get medical advice.
P319 Get medical help if you feel unwell.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Cosmetic raw material,API,Retatrutide,Tirzepatide,Semaglutide,intermediates
-
Location:
3-1-203 Green Home, No.1 Jianming South Road, Chang'an District, Shijiazhuang City, Hebei Province
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Total Employees:
5-10
-
Year of Establishment:
2025
-
-
Inquiry History284 Inquiries
Country Product Purchase Quantity Date Posted 
Germany
High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib
1 G Aug 25, 2026 
Vietnam
High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib
1 G Aug 18, 2026 
United States
High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib
1 G Jul 26, 2026 
Australia
High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib
1 G Aug 14, 2026 
Poland
High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib
1 G Jul 28, 2026 
United Kingdom
Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6
1 MT Sep 4, 2026 
Canada
Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6
500 MG Sep 1, 2026
Canada
Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6
500 MG Aug 25, 2026
United States
Factory Supply Erdafitinib CAS 1346242-81-6 99% High Purity FGFR Inhibitor API Powder
1 G Sep 3, 2026
United States
Hot Selling ERDAFITINIB 1346242-81-6 Factory Supply Raw Materials High Qulity Wholesale price
3 MT Jul 5, 2026
Australia
Erdafitinib
1 G Jul 18, 2026
Germany
Erdafitinib
500 MG Jul 28, 2026 
Cyprus
Erdafitinib
1 G Jul 22, 2026 
Bulgaria
Erdafitinib
500 MG Jun 18, 2026 
Switzerland
1g Erdafitinib raw powder >99% purity
1 G May 22, 2026 
Georgia
Erdafitinib
1 G Aug 19, 2026
United States
Erdafitinib
1 G Aug 27, 2026
United States
Erdafitinib
1 G Aug 29, 2026
Vietnam
Erdafitinib
360 G Sep 8, 2026 
Ireland
erdafitinib
1 G Sep 8, 2026 Post an enquiry for this product
